(PSMA) as a game-changing target for nuclear medicine at the 2011 European Association
of Nuclear Medicine meeting in Birmingham. The target had been identified 2 decades …

The recently published results of the VISION trial (1) represent the culmination of
translational research efforts that started in the 1980s and early 1990s with the discovery of …

In March 2021, Novartis announced a positive result for both primary endpoints of the
randomized phase III VISION study on 177Lu-PSMA-617 radioligand therapy (RLT). 177Lu …

The success of targeting and exploiting the prostate-specific membrane antigen (PSMA) for
diagnosis and radioligand therapy of prostate cancer has been remarkable. Unlike in early …

Without any doubt, the breakthrough of prostate-specific membrane antigen (PSMA)
targeting radiopharmaceuticals has stirred up nuclear medicine and radiopharmaceutical …

The recently presented and published results of the VISION phase III study of 177Lu-
PSMA617 for metastatic castrationresistant prostate cancer (1) are indeed one of the …

Simple Summary Imaging plays a crucial role in the accurate staging of prostate cancer.
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer cells, and …

Prostate-specific membrane antigen (PSMA) is highly expressed in PCa, which gradually
increases in high-grade tumors, metastatic tumors, and tumors nonresponsive to androgen …

After years of development and many published studies, prostate-specific membrane
antigen–targeted radioligand therapy recently reached a critical milestone on March 23 …

Prostate-specific membrane antigen (PSMA) is a type II transmembrane protein highly
expressed in almost all stages of prostate cancer (PCa)(> 90%)[1]. PSMA ligands for …